Automated estimation of disease recurrence in head and neck cancer using routine healthcare data

Abstract

We have demonstrated that our algorithm can be used to automate the interpretation of routine datasets to extract survival information for this sample of patients. It currently underestimates recurrence rates due to many patients not being well-enough to be treated for recurrent disease. With some further optimisation, this technique could be extended to a national level, providing a new approach to measuring outcomes on a larger scale than is currently possible. This could have implications for healthcare provision and policy for a range of different disease types.

Developing case‐finding algorithms for second events of oropharyngeal cancer using administrative data: A population‐based validation study

“…Ricketts et al developed an automated method to estimate the recurrence of head and neck cancers using a sample from a cancer center in the United Kingdom . In their cohort, there were 122 patients with head and neck cancer of whom 51 had oropharyngeal cancer.…”

“…One study explored the use of treatment data from one cancer center in the United Kingdom to identify recurrences of head and neck cancers and reported that their algorithm had moderate validity; however, the sample size of this previous study was small and not population based. More importantly, the algorithm was not applicable to Canada because of the differences in data availability and data systems.…”

A stratified analysis of the perioperative outcome of 17623 patients undergoing major head and neck cancer surgery in England over 10 years: Towards an Informatics‐based Outcomes Surveillance Framework

“…This is less relevant to a study focusing on perioperative outcomes of major surgery than it would be a long‐term oncological study, but as previously discussed, HES data can be linked to other data silos. Administrative data can also provide information about recurrence and disease‐free survival . As such, it has the capacity to provide the infrastructure for a disease‐specific responsive quality control framework for perioperative and oncological quality control, that once activated, could perpetually provide information about care quality and outcome at a frequency that is not achievable using other data submission exercises.…”

Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents

“…To select only patients with recurrent disease, only those individuals who initiated PPT 120 days or more after discontinuing platinum-based therapy were selected. 15 A live meeting of US-based oncologists (who had treated !5 SCCHN patients in the last 12 months) was convened to evaluate the validity of this previously published algorithm. 16 Those patients with progression prior to 120 days (i.e.…”